Sutter Health launches biobank registry to accelerate research into LATE
· News-MedicalSutter Health researchers have launched a biobank registry to accelerate research into LATE, a lesser-known form of dementia that can mimic Alzheimer's disease but stems from a different underlying cause.
The LATE Biobank Registry allows Sutter researchers to study biological samples and clinical data from patients who meet clinical criteria for LATE. By collecting samples over the course of patients' care, researchers hope to better understand the disease, develop and validate biomarkers and lay the groundwork for future clinical trials.
Greg Tranah, Ph.D., senior scientist and director, Sutter BiobankThe LATE registry demonstrates the broader promise of the Sutter Biobank: connecting biological samples with rich clinical information from patients receiving care across our system. By building research resources around diseases of aging, we can investigate why people experience conditions such as dementia differently and accelerate the search for biomarkers and more personalized approaches to prevention, diagnosis and treatment."
Dr. Shawn Kile, chair of Sutter Health's Advanced Neuroscience Service Line will present early findings from the registry Nov. 18 at the Clinical Trials on Alzheimer's Disease conference in Boston. His abstract presentation, "Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health," details the creation of the registry and its initial enrollment.
LATE, or limbic-predominant age-related TDP-43 encephalopathy, is associated with an abnormal buildup of the protein TDP-43 in areas of the brain critical to memory. Unlike Alzheimer's disease, LATE currently has no specific biomarkers or known treatments.
"Based on autopsy studies, we are learning that LATE pathology is showing up in approximately 40% of people age 80 and older. This is significant. Whether this is the primary driver of cognitive decline in some cases or co-pathology in other cases, it is important to understand," said Dr. Kile. "By collecting blood and cerebrospinal fluid from clinically suspected cases over time, this biobank registry can help us close current knowledge gaps and, ultimately, move toward a biomarker-driven diagnosis and more precise treatments for LATE."
The Alzheimer's Association released in 2025 clinical criteria for LATE. As biomarker testing makes it easier to identify Alzheimer's, researchers are also recognizing patients whose memory loss resembles Alzheimer's, but who test negative for amyloid and tau biomarkers associated with the disease. "Some of these patients may instead have LATE," says Dr. Kile.
Sutter's LATE Biobank Registry opened for enrollment in May 2026. At the time of abstract submission, researchers had identified 21 patients who met eligibility criteria, with six consented to participate. Eligible patients can enroll through participating Sutter Health affiliates across California. As the registry grows, it also creates a cohort of patients for future clinical trials of treatments targeting TDP-43.
"A health system like Sutter can leverage their patients to advance dementia research, from identifying patients in clinical care and collecting samples over time to studying new biomarkers and preparing for future trials. That connection between research and real-world care gives us an important opportunity to improve how neurodegenerative diseases such as LATE are recognized and, ultimately, treated," said Armen Moughamian, M.D., Ph.D., chief of memory for Sutter's Neuroscience Service Line and medical director of Sutter's Ray Dolby Brain Health Center at California Pacific Medical Center.
Source: